AI assistant
Mauna Kea Technologies — Capital/Financing Update 2017
Jan 2, 2017
1507_rns_2017-01-02_f8e203d6-be24-4406-909f-7647b0ed45c1.pdf
Capital/Financing Update
Open in viewerOpens in your device viewer
HALF-YEARLY REPORT ON THE LIQUIDITY CONTRACT WITH GILBERT DUPONT
Paris, France, January 2, 2017
Pursuant to the liquidity contract entrusted to Gilbert Dupont, on 31 December 2016 the following assets appeared on the liquidity account:
- Number of shares: 23,681
- Cash balance of the liquidity account: €94,289.08
As a reminder, at the time of the last Half-Yearly report on 30 June 2016, the following resources were booked to the liquidity account:
- Number of shares: 30,282
- Cash balance of the liquidity account: €81,237.08
About Mauna Kea Technologies
Mauna Kea Technologies is a global medical device company focused on eliminating uncertainties related to the diagnosis and treatment of cancer thanks to real time in vivo microscopic visualization. The Company's flagship product, Cellvizio, has received clearance to sell a wide range of applications in more than 40 countries, including the United States, Europe, Japan, China, Canada, Brazil and Mexico. For more information on Mauna Kea Technologies, visit www.maunakeatech.com
Mauna Kea Technologies Benoit Jacheet CFO [email protected] United States Zack Kubow / Lee Roth The Ruth Group 646-536-7020 / 7012 [email protected] [email protected]
U.S. Media Christopher Hippolyte The Ruth Group 646-536-7023 [email protected]
France and Europe NewCap - Investor Relations Florent Alba +33 (0)1 44 71 94 94 [email protected]